SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Restructurings
An SI Board Since September 2002
Posts SubjectMarks Bans
270 25 0
Emcee:  rkrw Type:  Unmoderated
Introduction Compact
A thread to note and discuss biotech restructurings which have been a new and growing phenomena in this bear market as biotechs buckle down to conserve cash.

Portfolio generated will use the opening price on the first day post restructuring announcement and a $1000 share purchase. This is a way to track performance post restructurings.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
270Achillion (ACHN) 20% in aftermath of Hep C program termination. Widely expectedtuck-2/22/2018
269AVEO trimming 17% of workforce [45 jobs] and trimming open positions by eliminapgo-neil-10/30/2012
268Qiagen (QGEN), about 9%. >> VENLO, The Netherlands , November 28, 2011 /Ptuck-12/5/2011
267The buyout speculation with respect to the pharma successor company is self-servDewDiligence_on_SI-10/20/2011
26650% of revenue from Humira for a few years, perhaps. When TriCor and Niaspan gotuck-10/20/2011
265ABT is splitting into two companies… PR: siliconinvestor.com Musings: silicoDewDiligence_on_SI-10/20/2011
264Cytokinetics (CYTK) 21% Message 27711735 Going from 105 (per Yahoo!) to 83. Ctuck-10/19/2011
263Amgen (AMGN) 2% all from R&D. Not clear yet if other divisions will also setuck-10/19/2011
262Array BioPharma Announces Restructuring Aligning Resources with Clinical Prograsim1-6/13/2011
261<i>Cancer drug companies SuperGen, Astex to merge in cash, stock deal</Steve Lokness-4/7/2011
260Another much deeper swing of the axe at Myrexis (MYRX): 41% investors.myrexis.ctuck-3/29/2011
259Roche to lay off 6300. They also terminate their partnership with ALNY. ALNY spgo-neil-11/21/2010
258>> But how much experience does Scangos have in restructuring a company antuck-11/10/2010
257Biogen to lay off about 650 employees [~13%], kill 11 programs and close their Spgo-neil-11/10/2010
256Myriad Pharmaceuticals -- soon to be "Myrexis" -- ~16% >>SALT Ltuck-6/8/2010
255Exelixis (EXEL) 40% >>Exelixis Announces Restructuring - Aligning Resourctuck-3/8/2010
254GTXI reduces headcount by about 28%. Still waiting on word from FDA on Torrmifenpgo-neil-12/14/2009
253That's what was left from DCGN's acquisition of MediChem in 2002. RegardDewDiligence_on_SI-10/4/2009
252DCGN closes Chicago operations. Cuts about 20% of staff. If anything, the futurpgo-neil-10/4/2009
251Renovo to cut a third of jobs after bid talks fail By Ben Deighton LONDON (Reutnigel bates-9/17/2009
250MBRX announced a corporate restructuring that will reduce its workforce by approidos-5/27/2009
249NBIX -50% SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Ikeokalani'nui-5/6/2009
248DSCO has recently reduced its workforce from 115 to 91 employees from its commeridos-5/5/2009
247failed.RockyBalboa-5/1/2009
246Zymogenetics (ZGEN) 32% Message 25607582 Cheers, Tucktuck-4/29/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News